Healthcare Realty’s Earnings Call Signals Steady Upside

Healthcare Realty Trust Incorporated ((HR)) has held its Q1 earnings call. Read on for the main highlights of the call.

Healthcare Realty Trust Incorporated’s latest earnings call struck an upbeat tone, underscoring strong operational execution and visible traction from its revamped strategy. Management highlighted record leasing, robust same-store NOI growth near 7%, healthier occupancy and lease economics, and disciplined capital allocation, while stressing that remaining challenges such as sub-target occupancy and refinancing risk are manageable.

Record Leasing Fuels Near-Term Growth

Healthcare Realty signed over 2.0 million square feet across roughly 290 leases in the quarter, marking an all-time high for the company and signaling solid demand for its medical office portfolio. A 1.4 million square foot active leasing pipeline and a signed-not-occupied pipeline of about 490,000 square feet, including redevelopment space, provide good visibility into future rent growth.

Same-Store NOI Surges, Guidance Edges Higher

Same-store cash NOI expanded 6.9% in the first quarter, a standout result that exceeded internal expectations and drove a modest guidance bump. Management raised its 2026 same-store NOI growth range by 25 basis points to 3.75%–4.75%, reflecting confidence in leasing spreads, occupancy gains, and margin improvement without overcommitting to recent strength.

Occupancy and Retention Trend in the Right Direction

Same-store occupancy climbed to 92.3%, up 110 basis points year-over-year, while total portfolio occupancy improved to 90.5%, moving closer to the company’s low-90s target. Retention remained impressive at 93.5%, suggesting that Healthcare Realty is keeping high-quality tenants in place even as it pushes for better rents and longer terms.

Lease Economics Support Long-Term Cash Flows

Average cash leasing spreads reached 4.2% in the quarter, with roughly one in four leases achieving spreads above 5%, pointing to healthy pricing power in key markets. Annual rent escalators averaged about 3.1% and the weighted average lease term approached eight years, reinforcing the durability of future cash flows despite some pockets of negative roll-downs.

FFO Growth and Dividend Coverage Remain Solid

Normalized FFO per share came in at $0.41, edging up from $0.40 in the prior quarter and prompting the company to lift its full-year normalized FFO guidance by $0.01 to a range of $1.59–$1.65. Funds available for distribution were $0.32 per share, with a quarterly dividend payout ratio of around 75%, leaving room for reinvestment while maintaining an attractive income profile.

Capital Allocation Focuses on Accretion

Healthcare Realty continued to lean into share repurchases, buying back $100 million of stock year-to-date, or 5.7 million shares, at an average price of $17.38, and still has $400 million of remaining authorization. The company also deployed capital into a joint venture acquisition with a pro rata investment of roughly $18 million and invested over $25 million into redevelopments during the quarter, prioritizing high-return projects.

Redevelopment Pipeline Drives High-Yield Upside

The redevelopment portfolio includes 23 properties that are about 64% pre-leased, offering built-in demand for future deliveries and supporting above-average returns. Recent activity featured a $25 million, 155,000-square-foot project that is fully pre-leased and the completion of a $35 million two-building medical office complex that is 98% leased, with overall redevelopment cash yields around 10% and targeted stabilized yields of 9%–12%.

Strengthening the Balance Sheet and Liquidity

To manage upcoming maturities and preserve flexibility, the company secured a fully committed $400 million unsecured delayed-draw term loan, expected to carry an all-in rate of about 4.8% and earmarked in part for a $600 million bond refinancing. Healthcare Realty also extended $400 million of interest rate swaps, locking SOFR at 3.3% through 2029, while a commercial paper program of roughly $250 million remains backstopped by its credit facility, supporting a year-end leverage goal in the mid-5x range.

Occupancy Gap Offers Both Drag and Opportunity

Despite progress, total portfolio occupancy at 90.5% still trails the company’s target range of 92%–93%, leaving a near-term drag on earnings but also a clear embedded growth engine as lease-up continues. Redevelopment vacancies and signed-not-occupied space are expected to convert into stabilized occupancy over time, giving investors a visible path to incremental NOI without heavy new investment.

Conservative Stance Despite Outperformance

Management’s guidance remains measured relative to the strong first-quarter print, with the same-store NOI midpoint around 4.25% and only a modest FFO per share increase. This cautious tone, including acknowledgment of selective negative leasing spreads and concessions on some renewals, suggests leadership prefers to under-promise even as operating metrics trend better than the headline ranges.

Managing Refinancing and Maturity Risks

The looming $600 million bond maturity in August represents a key financial milestone, but the delayed-draw facility and access to commercial paper mitigate refinancing risk in management’s view. The company acknowledged that reliance on short-term funding and clustered maturities requires careful balance sheet management, yet believes its liquidity position and committed term loan leave it well-positioned.

Valuation Friction and Cap Rate Headwinds

Executives noted that the stock trades around 11 times FFO, a level they view as too low given current growth and balance sheet strength, limiting the appeal of additional dispositions. With core medical office cap rates roughly in the 5.5%–6% range and only modest spread to core-plus assets, accretive buy-sell arbitrage remains constrained, encouraging a focus on internal growth and selective redevelopment instead of heavy transaction volume.

Residual Impact from Portfolio Optimization

Management emphasized that dilution from prior-year dispositions and deleveraging still weighs on reported growth metrics, masking stronger underlying operating trends. As the portfolio optimization cycle matures, the company expects these headwinds to fade, allowing core earnings growth north of 5% to become more visible to investors despite the mechanical drag from past asset sales.

Measured Guidance Points to Steady Upside

Looking ahead, Healthcare Realty slightly lifted its 2026 normalized FFO guidance to $1.59–$1.65 per share and nudged same-store NOI growth to 3.75%–4.75%, underpinned by 4.2% cash leasing spreads, 93.5% retention, and a robust leasing and SNO pipeline. The company plans to continue repurchasing shares, invest $50 million–$100 million into its joint venture partnership, advance redevelopments, and use the delayed-draw term loan to refinance the upcoming bond maturity while targeting leverage in the mid-5x range and maintaining roughly $1 billion of liquidity.

Healthcare Realty’s earnings call painted a picture of a company executing well on leasing and redevelopment while prudently managing its balance sheet and capital deployment. While occupancy has room to improve and refinancing needs remain in focus, the combination of strong same-store growth, improving margins, and a conservative outlook suggests a steady, internally driven earnings story that may not yet be fully reflected in the current valuation.